Cardiogenic shock (CS) remains associated with substantial morbidity and short-term mortality that often exceeds 40% despite contemporary therapy, and no recent randomized clinical trial has demonstrated an incremental improvement in outcomes.1 There is a wide spectrum of risk within CS populations, with severalfold variation in the likelihood of short-term survival between groups. Risk-tailored treatment has been proposed in other acute cardiovascular conditions, such as acute myocardial infarction (AMI). In high-risk patients with AMI, a more aggressive treatment strategy might be associated with better outcomes; if the same could be shown in patients with severe CS, this could lead to individualized treatment and improved survivorship.
展开▼
